drugset / Trial / NCT02333344

The Efficacy Study of Aclasta on Prosthetic Fixation in Postmenopausal Women After THA

NCT02333344

Phase 4 Withdrawn Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

It's to investigate the efficacy of Zoledronic acid treatment on the early prosthetic fixation in post-menopausal osteoporosis women under cementless total hip arthroplasty after 24-month observation.

Timeline

Start
2015-07-30
Primary completion
2020-01-28
Completion
2020-01-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified 5 mg

Indications

No indication recorded.